Adaptive Biotechnologies Corp
ADPT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001478320
In the last 90 days, Adaptive Biotechnologies Corp insiders filed 0 open-market purchases and 14 sales; 301 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; superinvestors Viking Global Investors and ARK Invest hold it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Adaptive Biotechnologies Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 14 filings
- 7 insiders, $46.3M in total
- Insiders trading
- 7
- Net value
- −$46.3M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Adaptive Biotechnologies Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lo Francis | Chief People Officer | 220,867 | Sep 18, 2026 | 12 |
| Bobulsky Susan | Chief Commercial Officer, MRD | 395,794 | Sep 17, 2026 | 10 |
| Owen Katey Einterz | Director | 66,100 | Sep 2, 2026 | 3 |
| Hershberg Robert | Director | 46,683 | Aug 20, 2026 | 3 |
| Robins Chad M | CEO and Chairman | 2,180,518 | Aug 19, 2026 | 9 |
| Neupert Peter M | Director | 130,625 | Aug 19, 2026 | 2 |
| Robins Harlan S | Chief Scientific Officer | 812,058 | Jul 23, 2026 | 11 |
| Benzeno Sharon | Chief Commercial Ofc Imm Med | 221,278 | Jun 30, 2026 | 5 |
| Griffin Michelle Renee | Director | 15,625 | Jun 29, 2026 | 4 |
| Piskel Kyle | Chief Financial Officer | 256,725 | May 20, 2026 | 7 |
| Rubinstein Julie | President and COO | 377,802 | Apr 29, 2026 | 15 |
| Pellini Michael J | Director | 69,690 | Mar 6, 2025 | 0 |
| Taylor Stacy L | SVP and General Counsel | 139,365 | Aug 23, 2024 | 0 |
| Peterson Tycho | Chief Financial Officer | 531,553 | Mar 6, 2024 | 0 |
| Sood Nitin | Chief Commercial Officer, MRD | 214,808 | Aug 8, 2023 | 0 |
| Adams R Mark | Chief Operating Officer | 175,361 | Apr 12, 2023 | 0 |
| Trigg Leslie | Director | 25,907 | Mar 8, 2023 | 0 |
| Conroy Kevin T | Director | 22,968 | Mar 8, 2023 | 0 |
| Baldo Lance | Chief Medical Officer | 17,171 | Mar 10, 2022 | 0 |
| Cohen Chad M | Chief Financial Officer | 21,604 | Dec 23, 2021 | 0 |
| Palaniappan Jyoti | SVP, Diagnostics, T-Detect | 9,158 | Jul 19, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)6:50 PM ET | Sep 15 | 2 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −1.20K | $27.00 | −$32.3K | −0.3%395.8K after | 10b5-1 |
| Sep 18, 2026 (view filing)8:17 PM ET | Sep 16 | 2 days | Lo FrancisChief People Officer | SSale | −115.4K | $28.06 | −$3.24M | −34.3%220.9K after | 2 lots10b5-1 |